US FOR THE MASSIVE INDOOR KIDS EXPO IN FREDERICKSBURG
largest sand box, Meeting a Minion and train rides are just the tip of the
iceberg of fun kids can have at the Annual Kids Expo Saturday and Sunday,
February 13 and 14th at the Fredericksburg Expo Center, Fredericksburg VA. Also
for the kids there are a petting zoo, Inflatables
– by KD’z Kidz World,
and more. Grownups can do some one-stop-shopping for the latest products and
services for growing families from national and local companies. More
information and advance tickets visit: FredericksburgKidsExpo.com
Our Fredericksburg office will be opening at 8:30am Tuesday, January 26, our Stafford office will be open normal hours.
Due to inclement weather our Stafford office will be CLOSED Monday, January 25th, our Fredericksburg office will be opening at 10am and closing at 5pm, please continue to check our Facebook Page and website for up to date information.
Due to inclement weather, both our Fredericksburg and Stafford offices will be opeing at 10 am, please continue to check our Facebook page and Website for up to date information.
Due to the impending weather, Allergy Partners of Fredericksburg will be closing at 1pm on Friday, January 22, please continue to check our website and Facebook page for up to date information.
See our Ask the Expert article in the January issue of Fredericksburg Parent Magazine (or online at http://www.fredericksburgparent.net/).
We'll also answer your questions LIVE during Ask the Expert, January 14
at 8PM at facebook.com/FredericksburgParent.
Our office will be closing at 5 pm today, with the last shot being given at 4:30 pm, we hope everyone has a Happy New Year!
corticosteroids were first shown to be effective in the treatment of acute
asthma in 1956. Since the 1970s the use of inhaled corticosteroids
(applied directly to the lungs with inhaler devices) has been proven to treat
asthma with fewer side effects than systemic corticosteroids. Inhaled
corticosteroids have consistently been shown in studies to decrease asthma
symptoms, improve lung function, reduce asthma exacerbations (resulting in less
emergency department visits and hospitalizations), decrease risk of death and
reduce the need for rescue asthma medications and oral corticosteroids. Inhaled
corticosteroids are the preferred medications for managing persistent asthma in
all ages, and the dose is based on the severity of the asthma.
used appropriately, inhaled corticosteroids have few adverse effects at low and
medium doses. The most common side effects include hoarseness of voice and oral
thrush, both of which can be reduced with proper inhaler technique and rinsing
of mouth after use. The higher dosages of inhaled corticosteroids can have more
important side effects, including the ability to suppress the adrenal axis and
even have long term effects on height when used in childhood (approximately 1.2
centimeters in the best study). However, the higher dosages of inhaled
corticosteroids are used to treat only severe asthmatics, who would
often require repeated doses of oral corticosteroids to open their airways and
the risk to benefit ratio may still be in favor of the use of inhaled
corticosteroids. Each patient is always unique and asthma is best cared
for by a physician who specializes in asthma care.
is the myth busted or true?
though, there is no dose of inhaled corticosteroid that has been shown to
On the News.
The FDA recently approved a new monoclonal antibody for add
on therapy for the treatment of severe asthma in patients older than 12 years of
How Does it Work?
Mepolizumab, which will also be known by its trade name
Nucala, is a monthly injection of a monoclonal antibody that inhibits
interleukin-5. Interleukin-5 is a cytokine which helps regulate eosinophils.
Eosinophils are white blood cells which can be a prominent feature of several
forms of asthma, especially allergic and severe persistent asthma. The allergic
reaction to an antigen often involves the development of eosinophils. The
underlying damage to the respiratory airway is often contributed by vast amounts
of eosinophil migration; increase up regulation of eosinophil production;
adhesion of eosinophils to the airway; and release of eosinophils toxic
products. Up to now the therapy to control eosinophils often rely on inhaled
and systemic steroids.
Is It For Me?
According to the World Health Organization (WHO) estimates
there are 235 million people living with asthma worldwide. It is estimated that
as many as 10% of those patients who have severe persistent asthma cannot
achieve good control with the available inhaled anti-inflammatory medicines and
may need chronic systemic steroids. It is this group of patients that new
therapy may provide a safe alternative for additional control. To date
specialists have been able to use a monoclonal antibody known as the Xolair also
known as Omalizumab which targeted the IgE antibody seen in some forms of
asthma. With this recent FDA approval, specialists such as the physicians at
Allergy Partners will be better able to select the appropriate therapy for the
more difficult asthma patient.
The most common side effects of Mepolizumab include
headaches, upper respiratory infections, asthma, local injection site reactions,
back pain and fatigue.
Welcome to our blog site! Stay tuned to get the latest news. We will share tips and techniques for living with and managing your Allergies & Asthma. We look forward to sharing useful resources with our patients!